PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess whether treatment with the study drug, panitumumab
given concomitantly with every 2 (Q2) week oxaliplatin-based chemotherapy and bevacizumab
improves progression-free survival (PFS) compared to treatment Q2-week with oxaliplatin-based
chemotherapy and bevacizumab alone. All subjects will receive Q2-week oxaliplatin- or
irinotecan-based chemotherapy and bevacizumab. Control arm subjects will not receive
concomitant panitumumab therapy.